<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274270</url>
  </required_header>
  <id_info>
    <org_study_id>2020-CKES-LUNG</org_study_id>
    <nct_id>NCT04274270</nct_id>
  </id_info>
  <brief_title>SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer</brief_title>
  <acronym>SBRTLCES</acronym>
  <official_title>Safety and Efficacy of Sequential Stereotactic Radiotherapy With S1 Combined With Endostar in the Treatment of Stage IV Lung Squamous Cell Carcinoma: Prospective, Multicenter, Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mianyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University International Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The fifth medical center of PLA general hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hiser Medical Center of Qingdao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Ruikang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GEM flower hospital of Liaohe oil field</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Worker's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian municipal central hospital affiliated of dalian medical university</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human recombinant endostatin preclinical studies have shown that the drug can inhibit
      endothelial cell proliferation, angiogenesis and tumor growth, still can directly induce lung
      cancer cell apoptosis, multiple clinical studies in human recombinant endostatin combined
      with chemotherapy treatment showed good antitumor efficacy and good safety.S1 is an oral
      fluorouracil derivative and an improved preparation of the antitumor drug tegafur.Multiple
      clinical studies have reported that S1 alone or S1 combined with chemotherapy is effective in
      Non small cell lung cancer(NSCLC).Unfortunately, none of the prospective clinical studies to
      date have systematically validated the safety and efficacy of antiangiogenic drugs combined
      with chemotherapy in patients with advanced pulmonary SCC.The investigators expect that endu
      combined with S1 will increase the efficacy of advanced lung squamous cell carcinoma.The
      purpose of this study was to evaluate the objective remission rate and safety of entu
      combined with oral S1 in the treatment of advanced lung squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigatorse enrolled patients with advanced lung squamous cell
      carcinoma to explore the safety and efficacy of sequential local radiotherapy combined with
      endodontic therapy.Plan to enroll 60 cases.For those who meet the inclusion criteria, medical
      history collection, physical examination, hematological examination and general imaging
      examination shall be completed before inclusion.Radiotherapy was performed with a cyberknife
      or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of
      radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with
      concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days
      during each cycle of chemotherapy, and 30mg was used every 24 hours.Treatment-related
      toxicity, treatment response and survival were followed up during treatment.Drug treatment
      until the tumor progresses, or there is an intolerable treatment-related toxicity, or no
      tolerance to further treatment.The treatment lasts for up to 3 years with good toxicity
      tolerance.During the treatment, the dose of teggio and endu is not adjusted. If serious
      adverse reactions occur, the drug should be treated actively and delayed.If the investigator
      determines that the treatment-related toxicity cannot be tolerated, the treatment is
      discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>the time interval of disease progression since the date of diagnosis</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LCR</measure>
    <time_frame>2 years</time_frame>
    <description>Local control rate criteria for short-term efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>2 years</time_frame>
    <description>adverse events and laboratory tests were graded according to NCI CTC AE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qol</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Radiotherapy Side Effect</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.</description>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>S1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Lung squamous cell carcinoma was confirmed by histopathology or cytopathology;

          2. Meet AJCC(8th edition, 2018) lung cancer stage IV standard;

          3. Lesions requiring SBRT;

          4. Measurable lesions must have at least one evaluable lesion judged according to RECIST
             1.1 standard, i.e., the longest diameter is at least 20mm);

          5. Age &gt;=18 years old;

          6. KPS &gt; = 70;

          7. Life expectancy of at least 3 months;

          8. Hematology, liver and kidney function and cardiopulmonary function can tolerate
             radiotherapy and chemotherapy.

        Exclusion Criteria:

          1. Lung adenocarcinoma or small cell lung cancer;

          2. Previous immunotherapy;

          3. Patients at risk of bleeding;

          4. Patients with any other malignant tumor before or now

          5. Patients diagnosed with esophagotracheal fistula,uncontrolled pleural
             effusion,pericardial effusion requiring repeated drainage,unhealed wounds,active
             gastric ulcers or fractures

          6. Patients suffering from poorly controlled heart disease or clinical symptoms, such as
             NYHA grade II or above cardiac dysfunction;unstable angina pectoris;Myocardial
             infarction occurred within 1 year;supraventricular or ventricular arrhythmia needs
             treatment or intervention;

          7. Patients with known central nervous system metastases.

          8. Patients with clinically suspected central nervous system metastasis must undergo
             enhanced CT or MRI within 28 days prior to randomization to exclude central nervous
             system metastasis.

          9. Pregnant or breastfeeding women;Women and men who are likely to become pregnant but do
             not want to use appropriate contraception;

         10. Other circumstances in which the investigator decides not to participate in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junjie Wang, Chairman</last_name>
      <phone>+8682264910</phone>
      <email>junjiewang_edu@sina.cn</email>
    </contact>
    <contact_backup>
      <last_name>Fei Xu</last_name>
      <phone>+8618511866032</phone>
      <email>xufeibysy@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Junjie Wang, Chairman</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei Xu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongqing Zhuang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhe Ji</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Qiu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suqing Tian</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The fifth medical center of PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xuezhang Duan, director</last_name>
      <phone>+8613621386161</phone>
      <email>13621386161@163.com</email>
    </contact>
    <investigator>
      <last_name>Xuezhang Duan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Xie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Sun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liuzhou Worker's Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guang XI</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chengjun Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi ruikang hospital</name>
      <address>
        <city>NanNing</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>ZuPing Lian, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>GuiYang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liang Liu, M D</last_name>
      <email>jinshatanwo@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qinghua Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian municipal central hospital affiliated of dalian medical university</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Nan Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GEM flower hospital of Liaohe oil field Tang-Du Hospital</name>
      <address>
        <city>Panjin</city>
        <state>Liaoning</state>
        <zip>124010</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Longhai Shen, M Med</last_name>
    </contact>
    <investigator>
      <last_name>Long hai Shen, M Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiser Medical Center of Qingdao</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peng Liu, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of Shanxi Medical University</name>
      <address>
        <city>TaiYuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiang Song, M Med</last_name>
      <email>songxianggeryuan@163.cob</email>
    </contact>
    <investigator>
      <last_name>Lei Zhang, M Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang Song, M Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tangdu hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>DongJie He, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mianyang Central Hospital</name>
      <address>
        <city>Mianyang</city>
        <state>Sichuan</state>
        <zip>621000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaobo Du, MD</last_name>
      <phone>+8613550822229</phone>
      <email>duxiaobo2005@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jie Li, M Med</last_name>
      <phone>+8615228324561</phone>
      <email>lijie.7181@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaobo Du, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Li, M Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huiming Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenyang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Meng Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University International Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jidong Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012 Dec;7(12):1775-1780. doi: 10.1097/JTO.0b013e31826aed28.</citation>
    <PMID>23154548</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Crinò L, Weder W, van Meerbeeck J, Felip E; ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v103-15. doi: 10.1093/annonc/mdq207.</citation>
    <PMID>20555058</PMID>
  </reference>
  <reference>
    <citation>Felip E, Stahel RA, Pavlidis N; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16 Suppl 1:i28-9.</citation>
    <PMID>15888743</PMID>
  </reference>
  <reference>
    <citation>William WN Jr, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009 Sep;136(3):701-709. doi: 10.1378/chest.08-2968. Epub 2009 Mar 24.</citation>
    <PMID>19318668</PMID>
  </reference>
  <reference>
    <citation>D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011 May 20;29(15):2066-70. doi: 10.1200/JCO.2010.32.6181. Epub 2011 Apr 11.</citation>
    <PMID>21482987</PMID>
  </reference>
  <reference>
    <citation>Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e341S-e368S. doi: 10.1378/chest.12-2361.</citation>
    <PMID>23649446</PMID>
  </reference>
  <reference>
    <citation>Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91.</citation>
    <PMID>15169807</PMID>
  </reference>
  <reference>
    <citation>Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Apr 10;28(11):1835-42. doi: 10.1200/JCO.2009.26.1321. Epub 2010 Mar 8.</citation>
    <PMID>20212250</PMID>
  </reference>
  <reference>
    <citation>Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.</citation>
    <PMID>24933332</PMID>
  </reference>
  <reference>
    <citation>Meng MB, Jiang XD, Deng L, Na FF, He JZ, Xue JX, Guo WH, Wen QL, Lan J, Mo XM, Lang JY, Lu Y. Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence. Radiother Oncol. 2013 Jan;106(1):130-7. doi: 10.1016/j.radonc.2012.10.022. Epub 2013 Jan 23.</citation>
    <PMID>23351845</PMID>
  </reference>
  <reference>
    <citation>Masuda T, Watanabe M, Fujitaka K, Hamai K, Ishikawa N, Doi M, Kitaguchi S, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Senoo T, Iwamoto H, Hamada H, Hattori N. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study. Mol Clin Oncol. 2018 Nov;9(5):539-544. doi: 10.3892/mco.2018.1705. Epub 2018 Aug 24.</citation>
    <PMID>30345049</PMID>
  </reference>
  <reference>
    <citation>Iwamoto Y, Mitsudomi T, Sakai K, Yamanaka T, Yoshioka H, Takahama M, Yoshimura M, Yoshino I, Takeda M, Sugawara S, Kawaguchi T, Takahashi T, Ohta M, Ichinose Y, Atagi S, Okada M, Saka H, Nakagawa K, Nakanishi Y, Nishio K. Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 1;21(23):5245-52. doi: 10.1158/1078-0432.CCR-14-3160. Epub 2015 Aug 7.</citation>
    <PMID>26253869</PMID>
  </reference>
  <reference>
    <citation>Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007 Feb;18(2):317-23. Epub 2006 Nov 1.</citation>
    <PMID>17079694</PMID>
  </reference>
  <reference>
    <citation>Yamashita Y, Kataoka K, Ishida T, Matsuura M, Seno N, Mukaida H, Miyahara E, Miyata Y, Okita R, Shimizu K, Watari M, Okumichi T, Okada M. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):612-6. doi: 10.1097/JTO.0b013e318174e05e.</citation>
    <PMID>18520800</PMID>
  </reference>
  <reference>
    <citation>Sugaya M, Uramoto H, Uchiyama A, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Hanagiri T, Yasumoto K. Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. Anticancer Res. 2010 Jul;30(7):3039-44.</citation>
    <PMID>20683052</PMID>
  </reference>
  <reference>
    <citation>Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer. 2013 Aug 6;109(3):538-44. doi: 10.1038/bjc.2013.374. Epub 2013 Jul 16.</citation>
    <PMID>23860537</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer, SBRT, s1,endostar</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

